Celsius Therapeutics
- Industry
- Biotechnology
- Founded Year
- 2018
- Headquarters
- Cambridge, Massachusetts, United States
- Employee Count
- 40
Key People
- Tariq Kassum - Chief Executive Officer and Board Member
- Jeanne Magram - Chief Scientific Officer
- Christoph Lengauer - Founder and Board Member
- Jeff Bluestone - Founder
- Vijay Kuchroo - Founder
- Aviv Regev - Founder
- Ramnik Xavier - Founder
- Ren Russo - Board Member
- Andrea van Elsas - Board Member
- Suzanne Jung Angell - Board Member
- Neil Exter - Board Member
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in biotechnology and medicine.
The presence of multiple founders and executives with proven track records in the biotech industry enhances the company's credibility and potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: The company's focus on precision medicines for cancer and autoimmune diseases addresses significant unmet medical needs.
By developing therapies for prevalent and serious conditions like cancer and autoimmune diseases, the company is addressing areas with high clinical demand and potential impact.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The biotechnology sector, especially in precision medicine, is highly competitive with numerous established players.
The presence of many competitors, including large pharmaceutical companies, makes it challenging to capture market share and requires strong differentiation.
- Technical Challenge
-
Aspect: Very Complex
Summary: Developing precision medicines involves intricate research and development processes.
The technical challenges inherent in creating targeted therapies necessitate substantial resources and time, potentially delaying product launch and increasing costs.
- Patent
-
Aspect: Very Strong
Summary: The company has secured robust intellectual property rights for its innovations.
Comprehensive patent protection ensures exclusivity, preventing competitors from replicating innovations and securing revenue streams.
- Financing
-
Aspect: Strategics
Summary: Acquisition by AbbVie provides substantial financial backing and resources.
While AbbVie's acquisition offers financial stability, reliance on one entity could constrain strategic decisions and innovation autonomy.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The lead candidate is in pivotal trials, indicating progress towards regulatory approval.
While pivotal trials are a critical step, the outcome remains uncertain, and any setbacks could delay or prevent market entry.
Opportunity Rollup
- Odds of Success
- 3.3
- Peak Market Share
- 3.65
- Segment CAGR
- 9.1%
- Market Segment
- Biotechnology
- Market Sub Segment
- Precision Medicine
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.18 |
| 2 | 0.55 |
| 3 | 1.28 |
| 4 | 2.56 |
| 5 | 3.65 |
Key Takeaway
Celsius Therapeutics, now part of AbbVie, is well-positioned in the precision medicine market but faces challenges due to competition and technical complexities.